SecBot SecBot
SC 13G/A ·Filed Oct 7, 2026

ATYR

aTYR PHARMA INC
NEUTRAL
Impact 3/10
Horizonweeks Processed19d 11h ago SEC0001623632-26-001548
Passive stake amendment
Actionable Insight • Neutral

Monitor for any future conversion to a 13D filing, which would signal activist intent. For now, Federated Hermes remains a passive holder at a stable 5.06% stake.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+5d
ATYR ▼ -34.14% at T+5d
NEUTRAL call -34.14% · α vs SPY -33.16% · entry $0.2783 → $0.1833
Next anchor: T+20d in 9d
Latest observation: T+12 -31.20% FF3 residual α
Entry = T+0 close
Oct 7, 2026
via day close
T+1d
-8.26%
call -8.26% · α -7.84%
$0.2553
settled 18d ago
T+5d
-34.14%
call -34.14% · α -33.16%
$0.1833
settled 12d ago
T+20d
Pending
in 9d
T+60d
Pending
in 2mo

Price Chart

Loading chart...

Executive Summary

Federated Hermes, Inc. filed an amendment to its Schedule 13G, reporting beneficial ownership of 4,965,414 shares of aTyr Pharma Inc. common stock as of September 30, 2026, representing 5.06% of shares outstanding. This is a routine passive stake update with no change in ownership level from the prior filing, indicating stable conviction from a top institutional holder.

Key Financial Metrics

Stake
5.06%
Investor
Federated Hermes, Inc.
Investor Type
mutual fund

Key Facts

  • Federated Hermes, Inc. reports beneficial ownership of 4,965,414 shares of aTyr Pharma Inc. common stock as of September 30, 2026.
  • The stake represents 5.06% of outstanding shares.
  • The filing is an amendment to Schedule 13G, confirming passive investment intent under Rule 13d-1(b).
  • Reporting persons disclaim beneficial ownership of the securities held by managed funds.

Financial Impact

No material financial impact; passive stake update with no change in ownership level.

Risk Factors

  • No change in stake suggests no new conviction signal; passive filing limits immediate market impact.
  • Any future reduction below 5% could be perceived as a loss of institutional support.

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001623632-26-001548
Document: atyrpharmaexhibit1.htm0001623632-26-001548
Document: atyrpharmaexhibit3trd.htm0001623632-26-001548
Document: atyrpharmaexhibit3acd.htm0001623632-26-001548
Document: 0001623632-26-001548-index-headers.html0001623632-26-001548
Document: 0001623632-26-001548-index.html0001623632-26-001548
Document: 0001623632-26-001548.txt0001623632-26-001548
13 reports for ATYR
Performance horizon
75% Hit rate @ T+5 3 of 4 directional calls Went positive at some point 4 of 4 best @ T+20▲ +51.37%Sep 22, 2026
Filters
Rows
Reports for ATYR — sortable, filterable
TypeNow
Oct 19, 2026
7d ago
Press Release
NEUTRAL ★ 3/10
$0.1717 $0.1534▼ −10.66%▼ −10.51%$0.1534 (−10.66%)
Oct 7, 2026
19d ago
SC 13G/A
NEUTRAL ★ 3/10
$0.2783 $0.1833▼ −34.14%▼ −33.16%$0.1534 (−44.88%)
Sep 22, 2026
4w ago
Institutional Cluster
BEARISH ★ 4/10
$0.3564 $0.3077▲ +13.66%▲ +12.48%$0.1534 (+56.96%)
Aug 7, 2026
11w ago
8-K
BEARISH ★ 7/10
$0.5289 $0.5189▲ +1.89%▲ +1.84%$0.1534 (+71.00%)
Jun 11, 2026
19w ago
Institutional Cluster
MIXED ★ 4/10
$0.4754 $0.4629▼ −2.63%▼ −3.06%$0.1534 (−67.73%)
Jun 8, 2026
20w ago
8-K
BEARISH ★ 7/10
$0.4556 $0.4433▲ +2.70%▲ +5.11%$0.1534 (+66.33%)
Jun 1, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$0.5200 $0.4560▼ −12.31%▼ −9.34%$0.1534 (−70.50%)
May 15, 2026
23w ago
8-K
BULLISH ★ 5/10
$0.5040 $0.4900▼ −2.78%▼ −3.74%$0.1534 (−69.56%)
May 15, 2026
23w ago
Press Release
NEUTRAL ★ 5/10
$0.5040 $0.4900▼ −2.78%▼ −3.74%$0.1534 (−69.56%)
May 11, 2026
24w ago
8-K
MIXED ★ 6/10
$0.5300 $0.5200▼ −1.89%▼ −1.96%$0.1534 (−71.06%)
Showing 10 of 13

US Market Status

Market Closed — Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 7, 2026